Search results
7 kwi 2021 · The prognosis of patients suffering from multifocal glioblastoma is very poor. As was shown before, craniotomy, employing maximum safe resection, is beneficial but already resecting more than 27.7% was associated with prolonged survival in univariate analysis for our cohort.
- Prognosis of patients with multifocal glioblastoma: a case-control ...
Patients with multifocal tumors experienced a significantly...
- Prognostic factors affecting outcome of multifocal or multicentric ...
In view of the advancement of imaging, there is a much...
- A Review of Newly Diagnosed Glioblastoma - PMC
Glioblastoma is an aggressive and inevitably recurrent...
- A systematic review of multifocal and multicentric glioblastoma
Multiple GBM is more genetically heterogeneous, aggressive...
- Patterns of care and survival in patients with multifocal glioblastoma ...
Multifocality was a poor prognostic factor for survival with...
- Prognosis of patients with multifocal glioblastoma: a case-control ...
Patients with multifocal tumors experienced a significantly shorter median overall survival of 6 months (95% CI 4-10 months), compared with the 11-month median survival (95% CI 10-19 months) of the matched solitary glioblastoma group (p = 0.02, log-rank test).
11 maj 2022 · Established prognostic factors are the extent of resection (EOR), performance status (PS) at diagnosis, histological features, patient age, and molecular biomarker status (mutations in isocitrate dehydrogenase 1, IDH1, and promoter methylation of O6-methylguanine DNA methyltransferase, MGMT) [3, 4].
3 maj 2023 · In view of the advancement of imaging, there is a much higher incidence of multiple GBM lesions at time of diagnosis than previously reported. Our study shows that mGBM has worse prognosis compared to GBM with singular lesion.
Glioblastoma is an aggressive and inevitably recurrent primary intra-axial brain tumor with a dismal prognosis. The current mainstay of treatment involves maximally safe surgical resection followed by radiotherapy over a 6-week period with concomitant temozolomide chemotherapy followed by temozolomide maintenance.
Multiple GBM is more genetically heterogeneous, aggressive and resistant to chemoradiotherapy than unifocal GBM, and has a worse prognosis. There is no international consensus on the treatment of multiple GBM.
9 mar 2024 · Multifocality was a poor prognostic factor for survival with a moderate effect. Prognostic factors for patients with mGBM were identified. Keywords: crossing midline; glioblastoma; multifocal; patterns of care; survival. © The Author (s) 2024.
